XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and our clinically validated DolaLock microtubule inhibitor payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors.
In 2022, we initiated a multicenter Phase 1 trial to investigate the safety, tolerability and anti-tumor activity of XMT-1660 in patients with solid tumors, including in breast, endometrial and ovarian cancers.
The U.S. Food and Drug Administration has granted Fast Track Designation to XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer.
XMT-1660 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of adult patients with advanced or metastatic triple-negative breast cancer.
For more information about our Phase 1 trial of XMT-1660, visit clinicaltrials.gov (NCT05377996).
Expanded Access Policy:
Expanded access, or compassionate use, is the use of an investigational product prior to regulatory approval and outside of a clinical trial. Mersana does not currently have an expanded access program or compassionate use program for any of our investigational products. We understand that for people living with cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trials is the best path to meet our goal of providing new treatments to patients with cancer. We encourage any person with cancer interested in gaining access to our investigational therapies to consult their physician(s) regarding the possibility of participating in one of our clinical trials.